FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

Только для исследовательских целей. Полный disclaimer →

Исследования/Semaglutide Trial Begins to Test Treatment for Alcohol Use Disorder and Obesity [NCT07949474]
Назад в Научную Библиотеку

Semaglutide Trial Begins to Test Treatment for Alcohol Use Disorder and Obesity [NCT07949474]

November 20, 2026
Share
Развивающиеся Исследования

Основано на развивающихся исследованиях. Эти выводы обещающи, но требуют дальнейшей проверки.

О данном анализе

Эта статья является AI-опороченной сводкой последнего опубликованного новости или клинического испытания. Она предназначена для быстрого, доступного обзора для сообщества исследований Peptide. Для полной точности всегда обращайтесь к исходному источнику, указанному ниже.

Semaglutide Trial Begins to Test Treatment for Alcohol Use Disorder and Obesity [NCT07949474]

A new clinical trial set to begin in 2027 aims to explore whether semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist commonly used for weight management, can also help individuals struggling with alcohol use disorder (AUD). The study, registered on ClinicalTrials.gov under identifier NCT07949474, is being conducted by the University of Minnesota and will involve 128 adults who are both obese and have AUD.

The trial's primary objective is to determine if semaglutide can effectively reduce alcohol consumption and improve overall health outcomes in this population. This research could open up new avenues for treating dual conditions that often co-occur, such as obesity and AUD, which currently lack targeted therapies.

Background

Alcohol use disorder is a significant public health concern, affecting millions of people worldwide. It can lead to numerous physical and mental health issues, including liver disease, heart problems, depression, and anxiety disorders. Additionally, many individuals with AUD also struggle with obesity, further complicating their treatment options. Current treatments for AUD are limited, and there's an urgent need for more effective medications that address both alcohol dependence and associated weight gain.

Semaglutide has already shown promise in managing type 2 diabetes and obesity through its mechanism of action on the GLP-1 receptor pathway. By mimicking natural peptides involved in appetite regulation and glucose metabolism, semaglutide can help reduce food intake and promote satiety. The potential for this medication to also impact alcohol consumption is intriguing, especially given the overlap between pathways involved in hunger and cravings.

Key Details

The upcoming trial will be a randomized, double-blind, placebo-controlled study lasting 45 weeks. Participants will receive either semaglutide or a placebo, with clinical assessments conducted regularly throughout the duration of the trial to monitor changes in alcohol use patterns and body weight. The primary outcome measures include reductions in alcohol consumption and improvements in overall health metrics.

Researchers hope that by targeting both obesity and AUD simultaneously, they can achieve better long-term outcomes for patients struggling with these conditions. Previous studies have suggested that addressing one condition may positively influence the other, making semaglutide a promising candidate for integrated treatment approaches.

Key Takeaways

  • Semaglutide Trial Launch: A new clinical trial will investigate whether semaglutide can help individuals with both AUD and obesity.
  • Dual Condition Management: The study aims to address two common health issues simultaneously, potentially offering more comprehensive care options.
  • GLP-1 Receptor Agonist Mechanism: Semaglutide's effects on GLP-1 receptors may extend beyond weight management to impact alcohol use behavior.
  • Clinical Trial Design: The trial will be randomized, double-blind, and placebo-controlled, ensuring robust data collection.

What This Means

For the peptide research community, this study represents a significant step forward in exploring novel therapeutic applications for existing peptides. If successful, it could pave the way for broader acceptance of GLP-1 receptor agonists like semaglutide as part of integrated treatment plans for complex health conditions involving both metabolic and behavioral components.

Moreover, this trial underscores the growing recognition of the interconnectedness between various health issues and the importance of holistic approaches in medical research. As more studies like these emerge, we can expect to see a richer understanding of how peptides can be leveraged across different therapeutic areas, ultimately benefiting patients with multifaceted health challenges.

---

Source: ClinicalTrials.gov — Published 2026-11-19

This article is for informational purposes only and does not constitute medical advice.

Примечание Редактора

Этот анализ был сгенерирован с использованием инструментов AI и проверен редакционной командой Peptide Contacts. Хотя мы стремимся к точности, содержание, сгенерированное AI, может содержать ошибки или пропуски. Мы призываем читателей проверить исходный источник полные детали, методология и данные.

Peptide Contacts предоставляет сводки научных исследований для информационных целей только. Это содержание не является медицинским советом. Всегда консультируйтесь с квалифицированным медицинским специалистом перед принятием каких-либо решений о здоровье.

Comments

Sign in to join the discussion

Эта статья была сгенерирована с использованием AI и может содержать неточности. Она предоставляется для информационных целей только и не является медицинским советом. Всегда проверяйте информацию в исходном источнике и консультируйтесь с квалифицированным медицинским специалистом перед принятием каких-либо решений о здоровье.